BR112017027252A2 - imunoglobulinas conjugadas a cys80 - Google Patents

imunoglobulinas conjugadas a cys80

Info

Publication number
BR112017027252A2
BR112017027252A2 BR112017027252-0A BR112017027252A BR112017027252A2 BR 112017027252 A2 BR112017027252 A2 BR 112017027252A2 BR 112017027252 A BR112017027252 A BR 112017027252A BR 112017027252 A2 BR112017027252 A2 BR 112017027252A2
Authority
BR
Brazil
Prior art keywords
immunoglobulins
chain variable
thiol
immunoglobulin
light chain
Prior art date
Application number
BR112017027252-0A
Other languages
English (en)
Inventor
Grasso Luigi
Spidel Jared
Bradford Kline James
Albone Earl
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of BR112017027252A2 publication Critical patent/BR112017027252A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

são fornecidos aqui métodos para gerar imunoglobulinas conjugadas, o método compreendendo: desnivelar uma cisteína na posição de aminoácido 80 ("cys80") em uma região variável de cadeia leve de uma imunoglobulina, em que a imunoglobulina compreende uma região variável de cadeia pesada e a região variável de cadeia leve; e conjugar um composto tiol reativo a cys80, em que o composto tiol reativo compreende um grupo tiol reativo. moléculas de ligação ao antígeno e métodos para gerar as mesmas, imunoglobulinas, bem como moléculas de ácido nucleico que codificam imunoglobulinas e células hospedeiras compreendendo as moléculas de ácido nucleico, imunoglobulinas conjugadas e regiões variáveis de cadeia leve para uso em uma imunoglobulina conjugada também são fornecidos.
BR112017027252-0A 2015-06-19 2016-06-17 imunoglobulinas conjugadas a cys80 BR112017027252A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182020P 2015-06-19 2015-06-19
US62/182,020 2015-06-19
PCT/US2016/038041 WO2016205618A1 (en) 2015-06-19 2016-06-17 Cys80 conjugated immunoglobulins

Publications (1)

Publication Number Publication Date
BR112017027252A2 true BR112017027252A2 (pt) 2018-08-28

Family

ID=56404289

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027252-0A BR112017027252A2 (pt) 2015-06-19 2016-06-17 imunoglobulinas conjugadas a cys80

Country Status (33)

Country Link
US (3) US10273310B2 (pt)
EP (2) EP3795591B1 (pt)
JP (2) JP6823606B2 (pt)
KR (1) KR20180021807A (pt)
CN (1) CN107949575B (pt)
AU (1) AU2016280190B9 (pt)
BR (1) BR112017027252A2 (pt)
CA (1) CA2989637C (pt)
CL (1) CL2017003273A1 (pt)
CO (1) CO2017013303A2 (pt)
CY (1) CY1123481T1 (pt)
DK (2) DK3310816T3 (pt)
ES (2) ES2829251T3 (pt)
HK (1) HK1252625A1 (pt)
HR (1) HRP20201489T1 (pt)
HU (2) HUE064407T2 (pt)
IL (1) IL256263B (pt)
LT (1) LT3310816T (pt)
MA (1) MA44207B1 (pt)
MD (1) MD3310816T2 (pt)
MX (1) MX2017016674A (pt)
MY (1) MY189024A (pt)
PE (1) PE20180498A1 (pt)
PH (1) PH12017502352A1 (pt)
PL (1) PL3310816T3 (pt)
PT (1) PT3310816T (pt)
RS (1) RS60943B1 (pt)
RU (1) RU2756101C2 (pt)
SG (1) SG10201913935RA (pt)
SI (1) SI3310816T1 (pt)
UA (1) UA124830C2 (pt)
WO (1) WO2016205618A1 (pt)
ZA (2) ZA201708619B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4055053A1 (en) 2019-11-07 2022-09-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
JP7399305B2 (ja) * 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
CA3184645A1 (en) 2020-06-05 2021-12-09 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
CN112694521B (zh) * 2020-12-02 2023-01-17 杭州百凌生物科技有限公司 一种人工多肽lh、其抗体及在病理检测中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187094C (zh) * 1998-04-28 2005-02-02 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US6904369B1 (en) * 2000-06-29 2005-06-07 The Trustees Of Columbia University In The City Of New York Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2006017759A2 (en) * 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
JP5791895B2 (ja) * 2007-05-04 2015-10-07 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 遺伝子操作されたウサギ抗体可変ドメイン及びその使用
EP2162469A4 (en) * 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
US20110033378A1 (en) * 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
EP2842575B1 (en) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2010118203A2 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
CN114246952A (zh) * 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
AR082205A1 (es) * 2010-07-12 2012-11-21 Covx Technologies Ireland Ltd Conjugados de anticuerpos multifuncionales
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
CA2882753C (en) 2012-08-21 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
RS58928B1 (sr) * 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions

Also Published As

Publication number Publication date
IL256263B (en) 2022-06-01
PH12017502352A1 (en) 2018-06-25
PE20180498A1 (es) 2018-03-09
MX2017016674A (es) 2018-08-01
AU2016280190B9 (en) 2022-05-19
MA44207B1 (fr) 2020-11-30
JP6823606B2 (ja) 2021-02-03
AU2016280190B2 (en) 2022-04-28
CN107949575A (zh) 2018-04-20
DK3310816T3 (da) 2020-10-12
HUE051315T2 (hu) 2021-03-01
ZA201708619B (en) 2022-11-30
ES2967613T3 (es) 2024-05-03
KR20180021807A (ko) 2018-03-05
RU2017146220A (ru) 2019-07-19
LT3310816T (lt) 2020-11-25
US20190202933A1 (en) 2019-07-04
HK1252625A1 (zh) 2019-05-31
CY1123481T1 (el) 2022-03-24
IL256263A (en) 2018-02-28
HRP20201489T1 (hr) 2020-12-11
NZ738496A (en) 2023-08-25
RU2756101C2 (ru) 2021-09-28
CO2017013303A2 (es) 2018-03-20
US11129904B2 (en) 2021-09-28
MY189024A (en) 2022-01-20
SG10201913935RA (en) 2020-03-30
ZA202102093B (en) 2023-03-29
PT3310816T (pt) 2020-10-19
US20230001004A1 (en) 2023-01-05
EP3310816A1 (en) 2018-04-25
JP7042876B2 (ja) 2022-03-28
EP3310816B1 (en) 2020-09-09
RS60943B1 (sr) 2020-11-30
MD3310816T2 (ro) 2021-01-31
UA124830C2 (uk) 2021-12-01
MA44207A (fr) 2018-12-26
HUE064407T2 (hu) 2024-03-28
US10273310B2 (en) 2019-04-30
SI3310816T1 (sl) 2020-12-31
CA2989637A1 (en) 2016-12-22
CN107949575B (zh) 2022-03-08
US20160369011A1 (en) 2016-12-22
EP3795591B1 (en) 2023-09-27
CA2989637C (en) 2023-01-10
CL2017003273A1 (es) 2018-12-21
ES2829251T3 (es) 2021-05-31
JP2020178717A (ja) 2020-11-05
WO2016205618A1 (en) 2016-12-22
RU2017146220A3 (pt) 2019-11-07
PL3310816T3 (pl) 2020-12-14
AU2016280190A1 (en) 2018-01-18
EP3795591A1 (en) 2021-03-24
DK3795591T3 (da) 2024-01-02
JP2018526975A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
BR112019003129A2 (pt) composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer.
BR112015026823A2 (pt) Polipeptídeo de cadeia pesada de imunoglobulina isolada, polipeptídeo de cadeia leve de imunoglobulina isolada, sequência de ácido nucleico isolada ou purificada, vetor, agente de ligação de proteína de morte-1 programada (pd-1) isolada, célula isolada, composição, e uso do agente de ligação da pd-1 isolada
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
BR112017003236A2 (pt) anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112016020065A2 (pt) sítios específicos para modificar anticorpos para fazer imunoconjugados
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
NZ739721A (en) Antigen binding constructs to target molecules
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
BRPI0812878C1 (pt) anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor
CO2020003882A2 (es) Anticuerpo multiespecifico
BR112016020009A2 (pt) anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
BR112017027252A2 (pt) imunoglobulinas conjugadas a cys80
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
AR103172A1 (es) Reducción selectiva de residuos de cisteina en anticuerpos il-17

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]